Coenzyme Q10 (CoQ10) is present in every cell of the body, where it functions as a powerful antioxidant and plays a central role in cellular energy production. Because heart muscle cells have exceptionally high energy demands, low CoQ10 status has been associated with greater severity of heart failure.
A randomized, controlled, multicenter study published in JACC: Heart Failure (December 2014; Volume 2, Issue 6, Pages 641–649) evaluated CoQ10 as an adjunct to standard therapy in patients with heart failure. The study enrolled 420 patients with moderate to severe chronic heart failure. Participants were randomly assigned to receive either 100 mg of CoQ10 three times daily or a placebo for two years, while continuing conventional heart failure treatment.
At 16 weeks, patients were assessed using the New York Heart Association (NYHA) functional classification, the six-minute walk test, and blood levels of BNP and NT-proBNP, biomarkers commonly used to evaluate heart failure severity. At this early time point, no significant differences were observed between the CoQ10 and placebo groups on these measures.
At the two-year follow-up, researchers evaluated major adverse cardiovascular events using a time-to-first-event analysis. The CoQ10 group experienced significantly better outcomes. Major cardiovascular events occurred in 15% of patients receiving CoQ10 compared with 26% in the placebo group. Cardiovascular mortality was lower in the CoQ10 group (9% vs. 16%), as was overall mortality (10% vs. 18%). Patients receiving CoQ10 also had fewer hospitalizations and showed greater improvement in NYHA functional class.
